KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients.

Yuqin Song, Qingyuan Zhang, Qingqing Cai, Yongping Song, Liling Zhang, Pengcheng He, Li Wang, Jamie Hirata, Lisa Musick, Rong Deng, Wenxin Liu, Xin Wang, Jun Zhu

J Cancer Res Ther 20(7) 2133-2140

PMID39792424
PMCID-
DOI10.4103/jcrt.jcrt_269_24
发表日期2025-01-10
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: Patients with transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have limited treatment options and poor outcomes. METHODS: This phase III study (NCT04236141) evaluated the efficacy and safety of polatuzumab vedotin plus bendamustine and rituximab (Pola+BR) versus BR in Chinese patients with transplant-ineligible R/R DLBCL to support regulatory submission in China. Patients were randomized 2:1 to receive Pola+BR or placebo+BR. The primary endpoint was complete response (CR) at the end of treatment (EOT) by positron emission tomography-computed tomography. RESULTS: Overall, 42 patients were analyzed (Pola+BR, n = 28; placebo+BR, n = 14). At data cutoff (July 12, 2021; median follow-up: 7.5 months), CR at EOT was 25.0% (7/28) with Pola+BR and 14.3% (2/14) with placebo+BR, 10.7% difference [95% confidence interval (CI): -19.0, 40.4]. The median investigator-assessed progression-free survival was 4.6 (95%CI: 3.1-6.4) months with Pola+BR and 2.0 (95% CI: 1.9-4.6) months with placebo+BR, with a 50% reduction in risk of progression or death (unstratified hazard ratio: 0.50; 95% CI: 0.24-1.05). The median overall survival was 10.6 [95% CI: 5.5-not evaluable (NE)] and 6.5 (95% CI: 6.0-NE) months, with a 45% reduction in risk of death. The incidence of Grade 3-4 adverse events was similar between Pola+BR (20/27 patients, 74.1%) and placebo+BR arms (11/14 patients, 78.6%). CONCLUSIONS: Efficacy findings were consistent with results of the GO29365 study (NCT02257567); treatment with Pola+BR led to clinically meaningful improvements in response rates in Chinese patients with transplant-ineligible R/R DLBCL with no new safety signals.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。